NIAID increase funding for Soligenix’s ricin toxin vaccine
The National Institute of Allergy and Infectious Diseases (NIAID) recently exercised an operation for the evaluation of Soligenix, Inc.’s ricin toxin vaccine, called RiVax, to fund additional animal efficacy studies. RiVax is a recombinant heat-stable subunit vaccine that contains a … Read More